Treatment of Neuronopathic Mucopolysaccharidoses with Blood–Brain Barrier-Crossing Enzymes: Clinical Application of Receptor-Mediated Transcytosis

Treatment of Neuronopathic Mucopolysaccharidoses with Blood–Brain Barrier-Crossing Enzymes: Clinical Application of Receptor-Mediated Transcytosis

Enzyme replacement therapy (ERT) has paved the way for treating the somatic symptoms of lysosomal storage diseases (LSDs), but the inability of intravenously administered enzymes to cross the blood–brain barrier (BBB) has left the central nervous system (CNS)-related symptoms of LSDs largely impervi...

Full description

Bibliographic Details
Main Authors:	Hiroyuki Sonoda, Kenichi Takahashi, Kohtaro Minami, Toru Hirato, Tatsuyoshi Yamamoto, Sairei So, Kazunori Tanizawa, Mathias Schmidt, Yuji Sato
Format:	Article
Language:	English
Published:	MDPI AG 2022-06-01
Series:	Pharmaceutics
Subjects:	lysosomal storage disease neuronopathic mucopolysaccharidosis blood–brain barrier neurodegeneration enzyme replacement therapy receptor-mediated transcytosis
Online Access:	https://www.mdpi.com/1999-4923/14/6/1240

Similar Items

Neuronopathic Types of Mucopolysaccharidoses: Pathogenesis and Emerging Treatments
by: L. A. Osipova, et al.
Published: (2015-11-01)

Investigating the neurobehavioral symptoms of neuronopathic Hunter syndrome
by: Nathan Grant
Published: (2020-03-01)

Response to: Investigating the neurobehavioral symptoms of neuronopathic Hunter syndrome
by: J.B. Eisengart, et al.
Published: (2020-03-01)

Neuronopathic Gaucher disease: Beyond lysosomal dysfunction
by: Nohela B. Arévalo, et al.
Published: (2022-08-01)

The final frontier – crossing the blood‐brain barrier
by: William S. Sly, et al.
Published: (2013-05-01)

A post hoc analysis of Projected Retained Ability Scores (PRAS) for the longitudinal assessment of cognitive functioning in patients with neuronopathic mucopolysaccharidosis II receiving intrathecal idursulfase-IT
by: Karen S. Yee, et al.
Published: (2023-11-01)

Glaucoma in mucopolysaccharidoses
by: Weijing Kong, et al.
Published: (2021-07-01)

Newborn screening in mucopolysaccharidoses
by: Maria Alice Donati, et al.
Published: (2018-11-01)

Clinical characteristics and somatic burden of patients with mucopolysaccharidosis II with or without neurological involvement: An analysis from the Hunter Outcome Survey
by: Heather Lau, et al.
Published: (2023-12-01)

Mucopolysaccharidoses and the blood–brain barrier
by: Onur Sahin, et al.
Published: (2022-09-01)

Dose-dependent effects of a brain-penetrating iduronate-2-sulfatase on neurobehavioral impairments in mucopolysaccharidosis II mice
by: Hideto Morimoto, et al.
Published: (2022-06-01)

Divergent developmental trajectories in two siblings with neuropathic mucopolysaccharidosis type II (Hunter syndrome) receiving conventional and novel enzyme replacement therapies: A case report
by: Kazuyoshi Tomita, et al.
Published: (2021-11-01)

Burden of caregivers of patients with neuronopathic and non-neuronopathic Gaucher disease in Japan: A survey-based study
by: Yuta Koto, et al.
Published: (2023-09-01)

Response to Letter to the Editor: Secondary ganglioside GM2 accumulation in mucopolysaccharidoses
by: Ainslie L.K. Derrick-Roberts
Published: (2022-03-01)

Viral delivery of a microRNA to Gba to the mouse central nervous system models neuronopathic Gaucher disease
by: Kasey L. Jackson, et al.
Published: (2019-10-01)

Endothelial Transcytosis of Lipoproteins in Atherosclerosis
by: Xinbo Zhang, et al.
Published: (2018-09-01)

Thirty-year clinical outcomes after haematopoietic stem cell transplantation in neuronopathic Gaucher disease
by: Aimee Donald, et al.
Published: (2022-06-01)

Cellular Organelle-Related Transcriptomic Profile Abnormalities in Neuronopathic Types of Mucopolysaccharidosis: A Comparison with Other Neurodegenerative Diseases
by: Karolina Wiśniewska, et al.
Published: (2024-03-01)

Identifying the genetic causes of phenotypically diagnosed Pakistani mucopolysaccharidoses patients by whole genome sequencing
by: Rutaba Gul, et al.
Published: (2023-04-01)

A global neuronopathic gaucher disease registry (GARDIAN): a patient-led initiative
by: Tanya Collin-Histed, et al.
Published: (2023-07-01)

Enzyme replacement with transferrin receptor-targeted α-L-iduronidase rescues brain pathology in mucopolysaccharidosis I mice
by: Sachiho Kida, et al.
Published: (2023-06-01)

Neurobehavioral phenotypes of neuronopathic mucopolysaccharidoses
by: Rita Barone, et al.
Published: (2018-11-01)

Biodistribution of Liposome-Encapsulated Bacteriophages and Their Transcytosis During Oral Phage Therapy
by: Jennifer Otero, et al.
Published: (2019-04-01)

Nonclinical safety evaluation of pabinafusp alfa, an anti-human transferrin receptor antibody and iduronate-2-sulfatase fusion protein, for the treatment of neuronopathic mucopolysaccharidosis type II
by: Ryuji Yamamoto, et al.
Published: (2021-06-01)

A New Pathogenesis of Albuminuria: Role of Transcytosis
by: Fang-Fang He, et al.
Published: (2018-06-01)

Electromyography in diagnostic of median nerve lesion in carpal tunnel syndrome of children with mucopolysaccharidoses
by: A. L. Kurenkov, et al.
Published: (2015-02-01)

Anesthesiological risks in mucopolysaccharidoses
by: Alessandra Moretto, et al.
Published: (2018-11-01)

Clinical and genetic characteristics of Gaucher disease according to phenotypic subgroups
by: Ju-Young Lee, et al.
Published: (2012-02-01)

Editorial: Neuronopathic lysosomal storage diseases - specific neuronal characteristics and therapeutic approaches
by: Stefanie Flunkert, et al.
Published: (2022-11-01)

Analysis of caregiver perspectives on patients with mucopolysaccharidosis II treated with pabinafusp alfa: results of qualitative interviews in Japan
by: Kimitoshi Nakamura, et al.
Published: (2024-03-01)

Bacteriophage Transcytosis Provides a Mechanism To Cross Epithelial Cell Layers
by: Sophie Nguyen, et al.
Published: (2017-12-01)

The Role of BAR Proteins and the Glycocalyx in Brain Endothelium Transcytosis
by: Diana M. Leite, et al.
Published: (2020-12-01)

Targeting Brain Drug Delivery with Macromolecules Through Receptor-Mediated Transcytosis
by: Yuanke Li, et al.
Published: (2025-01-01)

Functional independence of Taiwanese patients with mucopolysaccharidoses
by: Chung‐Lin Lee, et al.
Published: (2019-08-01)

Mucopolysaccharidoses: A rare cause for bilateral cloudy cornea
by: Jayshri Vipin Ekhar, et al.
Published: (2017-01-01)

Oral health status in patients with mucopolysaccharidoses
by: Elif Ballıkaya, et al.
Published: (2018-08-01)

Stimuli‐Responsive Nanocarriers for Transcytosis‐Based Cancer Drug Delivery
by: Zhehao Wang, et al.
Published: (2024-03-01)

Nationwide Newborn Screening Program for Mucopolysaccharidoses in Taiwan and an Update of the “Gold Standard” Criteria Required to Make a Confirmatory Diagnosis
by: Chih-Kuang Chuang, et al.
Published: (2021-08-01)

Major effect of transcytosis on nano drug delivery to pancreatic cancer
by: Xiangsheng Liu, et al.
Published: (2017-07-01)

Transcytosis to Cross the Blood Brain Barrier, New Advancements and Challenges
by: Victor M. Pulgar, et al.
Published: (2019-01-01)